U.S. Senator Jeanne Shaheen on Wednesday became the third Senate Democrat to say she would not seek reelection next year, ...

Novo Nordisk has filed for approval to extend the ... a childhood obesity specialist at the University of Minnesota Medical School in Minneapolis, pointed out that, left untreated, childhood ...

Wall Street’s stock markets plunged amid fears Donald Trump’s tariff trade war will hammer American growth. The tech-heavy ...

January 27, 2025 Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general ...

The Dow Jones plunged on the stock market today after President Donald Trump spoke about recession and tariffs. Tesla and Palantir took a dive.

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

The CEO of <strong>Novo Nordisk</strong> warned of the impact of tariffs on the pharmaceutical industry. Weight-loss drugs, including Ozempic and Wegovy, could cost ...

Gift 5 articles to anyone you choose each month when you subscribe. Danish pharmaceutical giant Novo Nordisk says about 13 million Australians are living with obesity or are overweight ...

From 'back burner' to full throttle Novo Nordisk's rare disease ambitions first began to shift when Lars Fruergaard Jørgensen donned the mantle of CEO in 2017. “One of the intuitions that Lars ...

Novo Nordisk has agreed its second acquisition in the space of a month of a biotech in the obesity category, snapping up fellow Danish company Embark Biotech for €15 million (around $16 million ...